BioSpace News Archive

Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8

Small molecule therapeutic inhibitors against coronaviruses included in agreement have demonstrated strong proof-of-concept and excellent efficacy data inMERS-CoV animal models

Caladrius Biosciences, Inc., announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority ’s Technology Business Tax Certificate Transfer Program.

Surgical navigation startup wins fourth small business award from NIH’s National Heart, Lung, and Blood Institute to extend novel technology to address peripheral vascular disease

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that CEO, John M. Climaco , will be issuing a shareholder webinar on April 22 nd , 2020 at 4:30pm ET to discuss the Company’s novel DNA-binding agent, WP1244, and to

AFYX Therapeutics (“AFYX”), a clinical stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, today announced that its Rivelin ® Clobetasol patch (“Rivelin-CLO”) met the primary and multiple secondary endpoints in a Phase 2b study in patients with oral lichen planus (“OLP”). In t

Heska Corporation announced that it will expand its leadership team, adding a Chief Commercial Officer, a Chief Administrative Officer, and a Managing Director and Chief Operating Officer, scil animal care company, to its current Executive Leadership Team.

The medical device company is also offering anyone free remote hearing checks and consultations, a limited-time discount, special financing and waived return fees

New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors

Ablexis, LLC , AlivaMab Discovery Services, LLC (“ADS”) and Berkeley Lights, Inc. today announced the rapid generation and recovery of sequences encoding a rich panel of human antibodies against the S1 spike protein of the S